EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Enhancing diversity of clinical trial populations in multiple sclerosis

Ruth Ann Marrie iD, Jeremy Chataway, Barbara E Bierer, Marcia Finlayson iD, Elena H Martinez-Lapiscina, Jennifer Panagoulias, Maria Pia Sormani iD, Mitzi Joi Williams, Lilyana Amezcua iD

Multiple Sclerosis Journal · 2023-08 · 29 (9) · 1174-1185

DOI: 10.1177/13524585231189677 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 09.08.2023. Verfasst von Ruth Ann Marrie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Demographic characteristics, social determinants of health (SDoH), health inequities, and health disparities substantially influence the general and disease-specific health outcomes of people with multiple sclerosis (MS). Participants in clinical trials do not represent all people with MS treated in practice.

Objective

To provide recommendations for enhancing diversity and inclusion in clinical trials in MS.

Methods

We held an international workshop under the Auspices of the International Advisory Committee on Clinical Trials in MS (the “Committee”) to develop recommendations regarding diversity and inclusivity of participants of clinical trials in MS. Workshop attendees included members of the Committee as well as external participants. External participants were selected based on expertise in trials, SDoH, health equity and regulatory science, and diversity with respect to gender, race, ethnicity, and geography.

Results

Recommendations include use of diversity plans, community engagement and education, cultural competency training, biologically justified rather than templated eligibility criteria, adaptive designs that allow broadening of eligibility criteria over the course of a trial, and logistical and practical adjustments to reduce study participant burden. Investigators should report demographic and SDoH characteristics of participants.

Conclusion

These recommendations provide sponsors and investigators with methods of improving diversity and inclusivity of clinical trial populations in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansEthnicityResearch DesignSurveys and QuestionnairesClinical Trials as Topic

Stichwörter der Autor:innen

Multiple sclerosisclinical trialsdiversitysocial determinants of health

Autor:innen und Institutionen

  • Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK/National Institute for Health Research,…
  • The Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Cambridge, MA, USA/Harvard Medical School, Boston, MA, USA.
  • School of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
  • Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelon…
  • Foundation for Angelman Syndrome Therapeutics, Austin, TX, USA.

ORCID-Profile: Ruth Ann Marrie, Marcia Finlayson, Maria Pia Sormani, Lilyana Amezcua

Zitieren

APA

Marrie, R. A., Chataway, J., Bierer, B. E., Finlayson, M., Martinez-Lapiscina, E. H., Panagoulias, J., Sormani, M. P., Williams, M. J., & Amezcua, L. (2023). Enhancing diversity of clinical trial populations in multiple sclerosis. Multiple Sclerosis Journal, 29(9), 1174-1185. https://doi.org/10.1177/13524585231189677

Vancouver

Marrie RA, Chataway J, Bierer BE, Finlayson M, Martinez-Lapiscina EH, Panagoulias J, et al. Enhancing diversity of clinical trial populations in multiple sclerosis. Multiple Sclerosis Journal. 2023;29(9):1174-1185. doi:10.1177/13524585231189677

BibTeX
@article{Marrie2023,
  author = {Marrie, Ruth Ann and Chataway, Jeremy and Bierer, Barbara E and Finlayson, Marcia and Martinez-Lapiscina, Elena H and Panagoulias, Jennifer and Sormani, Maria Pia and Williams, Mitzi Joi and Amezcua, Lilyana},
  title = {Enhancing diversity of clinical trial populations in multiple sclerosis},
  journal = {Multiple Sclerosis Journal},
  year = {2023},
  volume = {29},
  number = {9},
  pages = {1174--1185},
  doi = {10.1177/13524585231189677}
}
Kostenlos starten →